Plasma Expressor Machine Market size was over USD 109.2 million in 2023 and is projected to reach USD 170.78 million by 2036, growing at around 3.5% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of plasma expressor machine is evaluated at USD 112.26 million. Plasma expressor machine is a device used to separate plasma, RBC, WBC and platelets from the blood. Basically, it is used for easy and efficient blood component separation in any manner. Various diseases, such as, leukopenia or neutropenia require only the white blood cells, while dengue treatment requires platelets separately. The growth of the market can be attributed to the growing need for any specific component of blood to treat various rare diseases. Blood cancer, such as, leukemia, lymphoma, and myeloma, are the primary disorders which entail the need for plasma expressor machines.
Moreover, the growing prevalence of blood cancer is estimated to boost the plasma expressor machine market growth. As per the data by the World Cancer Research Fund (WCRF), an estimated 18.1 million cancer cases were diagnosed around the world in 2020. Out of these, 18,094,716 new cancer cases were reported in 2020 itself. Among these, leukemia accounted for 474,519 cases, Hodgkin lymphoma accounted for 83,087 cases, and multiple myeloma accounted for 176,404 cases globally.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024–2036 |
|
CAGR |
3.5% |
|
Base Year Market Size (2023) |
USD 109.2 million |
|
Forecast Year Market Size (2036) |
USD 170.78 million |
|
Regional Scope |
|
The market is segmented by application into plasma separation, chemical research, blood testing, pharmaceutical research, and others, out of which, the plasma separation segment is anticipated to hold a substantial share in the global plasma expressor machine market over the forecast period on account of increasing demand for plasma transfusion for treatment of pneumonia caused by coronavirus infection. Certain chronic conditions, such as, disseminated intravascular coagulation (DIC), also requires plasma transfusion. Such factors are estimated to boost the segment growth.
Our in-depth analysis of the global market includes the following segments:
|
By Type |
|
|
By Application |
|
|
By End-User |
|
On the basis of geographical analysis, the global plasma expressor machine market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in the North America industry is estimated to hold largest revenue share by 2036, led by high prevalence of leukemia and lymphoma in the region. According to the data by the American Cancer Society, in the United States, about 60,650 new cases of leukemia were reported in 2021, out of which, 20,050 cases of acute myeloid leukemia (AML) were reported. The market in the Asia Pacific region is anticipated to gain the largest market share throughout the forecast period growing incidences of blood cancer, along with rising health awareness amongst the people. Moreover, the increasing adoption of advanced medical technology, such as plasma expressor machine, is further estimated to boost the plasma expressor machine market growth.
January 27, 2022: Lonza Group to collaborate with HaemaLogiX Ltd., to manufacture next clinical batch of multiple myeloma drug candidate, KappaMab.
December 08, 2021: ThermoGenesis Holdings, Inc. to join hands with Contract Development Manufacturing Organization (CDMO) to make Cell and Gene therapies available to the maximum patients.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?